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Objective: To evaluate the clinical practice and short-term efﬁcacy of microwave endometrial ablation
(MEA) to treat menorrhagia, and to identify prognostic factors for optimal outcomes.
Methods: We performed MEA in 22 women with menorrhagia between October 2012 and December
2013. To evaluate efﬁcacy, objective and subjective variables were measured using medical records and
patients' pre- and postoperative responses to a written questionnaire with a visual analog scale (VAS)
scored from 0 to 10 for each symptom. MEA outcome was evaluated 6 months after treatment. Patients
with amelioration of menorrhagia and no anemia were deﬁned as the effective group, and the others
were deﬁned as the noneffective group. Effective patients requiring no hormonal therapy were deﬁned
as the highly effective group. To identify prognostic factors, background factors were compared between
the highly effective group and the other groups.
Results: Uterine ﬁbroids and adenomyosis were diagnosed in 68% and 32% of patients, respectively. The
median VAS score of postoperative pain was 1.0, and that of satisfaction was 8.1. Hemoglobin concen-
tration, menstrual bleeding volume, menstrual duration, menstrual pain, vaginal discharge, and fatigue
were ameliorated in the postoperative period. The effective group, the highly effective group, and the
noneffective group included 95%, 84%, and 5% of patients, respectively. The uterine corpus cavity was
signiﬁcantly shorter in the highly effective group than in the other groups.
Conclusion: MEA was safe and effective. The short-term efﬁcacy rate of MEA for alleviating menorrhagia
symptoms was 95%. Optimal outcomes were correlated with a shorter uterine corpus cavity.
Copyright © 2015, The Asia-Paciﬁc Association for Gynecologic Endoscopy and Minimally Invasive
Therapy. Published by Elsevier Taiwan LLC. All rights reserved.Introduction
Endometrial ablation is considered an important surgical option
for the treatment of menorrhagia.1 In Japan, microwave endome-
trial ablation (MEA) using a frequency of 2.45 GHz was described
and developed as an original applicator for use by Kanaoka et al2 in
2001. After the Japanese Ministry of Health, Labour, and Welfare
authorized the use of MEA as an advancedmedical therapy in 2009,
MEA has been offered in a few approved institutions and facilities.s of interest relevant to this
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for Gynecologic Endoscopy and MinimIn April 2012, MEA was approved by the national health insurance
system in Japan as a covered treatment for menorrhagia. At that
time, we began providing MEA in our hospital. Several researchers
evaluated the efﬁcacy of MEA based on the condition during 3e24
months after operations. Ishikawa et al3 showed that no patient
experienced recurrent menorrhagia for > 6 months after MEA.
Therefore, the short-term postoperative conditionwas evaluated in
6 months in this research. The purposes of this research were to
evaluate the clinical practice and short-term efﬁcacy of 2.45-GHz
MEA to treat menorrhagia and to identify the prognostic factors
associated with optimal MEA outcomes.
Materials and methods
Patient selection
Patients with symptoms of menorrhagia who were no longer
bearing children and with no uterine malignancy were initiallyally Invasive Therapy. Published by Elsevier Taiwan LLC. All rights reserved.
Table 1
Characteristics of the 22 patients who received microwave endometrial ablation to
treat menorrhagia.
Factors Median Range n %
Age (y) 46.5 39e54
Parity 2 0e4
Previous cesarean delivery 6 27.3
Obesity (BMI  25) 4 18.2
Initial anemiaa 18 81.8
Initial hemoglobin concentration (g/dL) 8.6 4.0e13.6
Organic diagnosis causing menorrhagia
Uterine ﬁbroids 15 68.2
Multiple ﬁbroids 9 60.0
Submucosal ﬁbroids 8 53.3
Adenomyosis 7 31.8
Functional menorrhagia 0 0
Patient complaints
Heavy menstrual bleeding 22 100
Prolonged menstruation 10 45.5
Painful menstruation 11 50.0
Uterine corpus cavity length (cm) 5.5 3.4e7.5
Preoperative use of iron supplement 18 81.8
Preoperative pseudomenopausal therapy 15 68.2
Preoperative oral hormonal medication 1 4.5
BMI ¼ body mass index.
a Initial hemoglobin concentration < 12.0 g/dL.
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receive MEA was individually decided on the basis of preoperative
assessment using ultrasonography and/or magnetic resonance
imaging. In principle, patients whose menorrhagia was not easy to
control by conservative therapy were deemed to be good candi-
dates. Patients whose uterine cavity was too large or too complex in
shape to appropriately and safely provide MEA were excluded.
Patients who preferred hysterectomy, which would furnish a per-
fect effect for menorrhagia in exchange for the invasiveness, were
excluded as well. Before undergoing MEA, patients received an iron
supplement, pseudomenopausal therapy (subcutaneous leuprolide
acetate), and an oral hormonal medication (dienogest or an estro-
geneprogestin combination) if necessary.
Ablation procedure
The microwave system used in this research was composed of a
Microtaze device and a Sounding Applicator (Alfresa Pharma,
Osaka, Japan). The former is a power generator of 2.45-GHz mi-
crowaves, and the latter is an intrauterine applicator that irradiates
microwaves from its tip. The applicator is 4 mm in diameter and
curved to access the endometrium easily, and it reaches to a
maximum distance of 18 cm. MEA was performed according to the
procedure guidelines described previously.4 The microwave gen-
erator's output was set to 70 watts for 50 seconds for each irradi-
ation. Transabdominal ultrasonography was used for intraoperative
monitoring. Immediately before and after the procedure, as well as
during the procedure if necessary, hysteroscopy was used to visu-
alize the ablated area. Microwave irradiation was repeated until a
sufﬁcient area of the uterine corpus endometrium had been abla-
ted. General anesthesia was used, and a nonsteroidal anti-
inﬂammatory drug was administered intraoperatively.
Research design
We performed MEA in 22 women with menorrhagia between
October 2012 and December 2013. To evaluate MEA efﬁcacy, sub-
jective and objective variables were measured. Objective variable
data were drawn from patients' medical records, including their
laboratory test results, and subjective variables were measured
using patients' responses to a written questionnaire survey. Pre-
and postoperative subjective symptom ratings of each patient were
obtained using a questionnaire with a visual analog scale (VAS)
scored from 0 to 10 for each symptom. The questionnaire survey
was performed and MEA outcome was evaluated by each patient 6
months after treatment. At that time, patients with amelioration of
menorrhagia and no anemia were deﬁned as the effective group,
and the others were deﬁned as the noneffective group. Ameliora-
tion of menorrhagia was deﬁned by self-report as mentioned in the
patient's medical record 6 months after MEA, or by a subjective
estimate of postoperative menstrual bleeding volume that was
decreased to half or less than the preoperative volume in the pa-
tient. Moreover, the effective group was subdivided into two
groups: those whose postoperative symptoms required no hor-
monal therapy comprised the highly effective group, whereas those
who continued to use additional hormonal therapy in the post-
operative period were classiﬁed as the fairly effective group.
To evaluate MEA efﬁcacy in detail, each patient's pre- and
postoperative variables were compared. To identify the prognostic
factors associated with the optimal outcomes, background factors
were compared between the highly effective group and the other
groups. Correlation was measured between the length of the
uterine corpus cavity (from the anatomical internal os to the upper
edge of the endometrium) and the number of microwave irradia-
tion sessions required.This research was planned and performed on the basis of the
approval of the research ethics committee in our hospital. Each
patient's written informed consent to the research was obtained
along with the responses to the questionnaire.
Data were analyzed using JMP version 8.0 (SAS Institute, Cary,
NC, USA) and R version 2.13. Two-tailed p values were calculated
using univariate methods including the ManneWhitney U test,
Wilcoxon signed rank test, McNemar test, Chi-square test, and
Pearson product-moment correlation coefﬁcient. A p value < 0.05
was considered signiﬁcant.Results
The characteristics of the 22 patients who received MEA are
shown in Table 1. No patients received a diagnosis of functional
menorrhagia; all patients had either uterine ﬁbroids or adeno-
myosis. Summarized data concerning the MEA procedures are
shown in Table 2. On the whole, MEA yielded high levels of patient
satisfaction with minimal postoperative pain. The only clinically
problematic adverse event occurred in a patient with a single
intramural ﬁbroid of 55 mm in diameter. The patient had a fever
with purulent vaginal discharge 1 week after MEA. The condition
was diagnosed as bacterial endometrisis, and she had to be brieﬂy
admitted to our hospital for intravenous antibiotics.
To evaluate MEA efﬁcacy in detail, pre- and postoperative vari-
ables of each patient were compared. An iron supplement was
administered to 81.8% and 5.3% of patients (p < 0.001 by McNemar
test), pseudomenopausal therapy was administered to 68.2% and
10.5% (p < 0.001), and oral hormonal medication was administered
to 5.3% and 10.5% (p ¼ 1.0) of the 22 women in the pre- and post-
operative periods, respectively. Changes in hemoglobin concen-
tration and patients' subjective symptom ratings are presented in
Figure 1. Hemoglobin concentration (median preoperative score,
median postoperative score, and median variation were 8.6, 13.5,
and þ5.3, respectively), menstrual bleeding volume (10, 1.0,
and 8.0, respectively), menstrual duration (7.0, 2.5, and 3.5,
respectively), menstrual pain (7.5, 0.5, and 4.0, respectively),
vaginal discharge (4.8, 1.6, and 2.4, respectively), and fatigue (7.5,
2.0, and 5.0, respectively) ameliorated in the postoperative
period.
Table 2
Summarized data concerning microwave endometrial ablation procedures.
Variables Median Range n %
No. of microwave irradiation sessions per operation 7.0 5e12
Operative time (min)a 18 10e43
Postoperative use of painkiller on the operative day 6 27.3
Postoperative use of painkiller on and after the
next day
4 18.2
VAS score of postoperative pain (points)b 1.0 0e10
VAS score of satisfaction (points)c 8.1 2.5e10
VAS ¼ visual analog scale.
a The duration from starting the ﬁrst irradiation to ascertaining necessary and
sufﬁcient ablation by hysteroscopy.
b A lower score indicates milder pain.
c A higher score indicates a higher level of satisfaction.
N. Matsumoto et al. / Gynecology and Minimally Invasive Therapy 4 (2015) 76e8078In the 19 patients whose postoperative conditions were ob-
tained, amenorrhea was observed in 52.6% (10/19) in the post-
operative period. Only one patient reported no improvement in the
menstrual bleeding volume. She received a diagnosis of multiple
uterine ﬁbroids, including a 56-mm submucosal ﬁbroid. Her uter-
ine corpus cavity measured 7.5 cm, and the operator performed 12
microwave irradiation sessions during the patient's MEA proce-
dure. Her pre- and postoperative ratings of menstrual bleeding
volume were 10 and 10, respectively.
TheMEAoutcomeswere largely positive: 94.7% (18/19) of patients
were classiﬁed in the effective group, and 84.2% (16/19) also met the
criteria for the highly effective group, whereas only 5.3% (1/19) of
patients were classiﬁed into the noneffective group. SubsequentFigure 1. Changes in hemoglobin concentration and patients' subjective symptom ratings
calculated using Wilcoxon signed-rank tests.hysterectomies were performed in two patients, although these
eventsoccurred after thepostoperative studyperiodof 6months.One
case was the aforementioned patient who underwent hysterectomy
11 months after MEA. The second patient received a diagnosis of
adenomyosis and pelvic endometriosis with severe anemia and
dysmenorrhea. Although MEA reduced the patient's reported men-
strualbleedingvolume,herdysmenorrheawasnot relievedandpelvic
endometriosis was exacerbated. After MEA, she received pseudome-
nopausal therapy,which alsodid not produce sufﬁcient improvement
in her symptoms. Therefore, the patient underwent hysterectomy
with affected-side salpingo-oophorectomy 1 year after MEA.
To identify the prognostic factors associated with the optimal
outcomes, background factors were compared between the highly
effective group and the other groups (Table 3). The mean uterine
corpus cavity length was signiﬁcantly shorter in the highly effective
group than in the other groups, and no patients in this group had a
cavity length greater than 7 cm.
The correlation between the uterine corpus cavity length and
the number of microwave irradiation sessions required for treat-
ment was analyzed (Figure 2), and a positive linear correlation was
observed (r ¼ 0.54, p ¼ 0.008).Discussion
MEA was safely and effectively provided in our hospital. The
short-termefﬁcacy rate ofMEA for the treatmentofmenorrhagiawas
estimated to be 94.7%. The optimal MEA outcomes were associated
with a shorter uterine corpus cavity. A positive linear correlationwasto evaluate the efﬁcacy of microwave endometrial ablation in detail. The p values are
Table 3
Comparison of background factors between the highly effective group and the other
groups in the 19 patients whose postoperative ratings were obtained.
Factors Highly effective
group
Other
groups
p
Age (y) 45.5 46 0.96
Parity 2 2 0.39
Previous cesarean delivery (%) 37.5 0 0.20
Obesity (BMI  25; %) 25.0 0 0.33
Initial hemoglobin concentration (g/dL) 8.4 9.7 0.91
Organic diagnosis causing menorrhagia (%)
Uterine ﬁbroids 68.8 33.3 0.25
Multiple ﬁbroids 63.6 100 0.46
Submucosal ﬁbroids 63.6 100 0.46
Adenomyosis 33.3 68.8 0.25
Patient complaints (%)
Prolonged menstruation 43.8 33.3 0.74
Painful menstruation 50.0 100 0.11
Uterine corpus cavity length (cm) 5.5 7.2 0.010
VAS scores of patients' subjective preoperative conditions (points)
Menstrual bleeding volume 10 7.5 0.18
Menstrual duration 7 5 0.19
Abnormal vaginal bleeding 0 5 0.068
Menstrual pain 5 8 0.21
Chronic pelvic pain 2.5 0 0.79
Vaginal discharge 5 2.4 0.27
Fatigue 7.5 5 0.28
Preoperative pseudomenopausal therapy (%) 68.8 66.7 0.95
Data are presented as the median or proportion in each group. The p values were
calculated using Chi-square or ManneWhitney U tests.
BMI ¼ body mass index; VAS ¼ visual analog scale.
Figure 2. Correlation between the uterine corpus cavity length and the number of
microwave irradiation sessions, measured using the Pearson product-moment corre-
lation coefﬁcient.
Table 4
Short-term efﬁcacy of microwave endometrial ablation reported in the recent literature.
Year Researchers n Period of assessment for
therapeutic effect (mo after MEA)
Reduction in men
bleeding volume
2009 Sambrook et al7 157 12 76
2012 Singh et al8 68 6e18 84
2012 Tsuda9 25 3 96
2012 Ishikawa et al3 55 6e24 92
2014 Nakayama et al10 76 6 95
2014 This research 19 6 95
Data are presented as %, unless otherwise indicated.
VAS ¼ visual analog scale.
a These were performed after the postoperative study period of 6 months.
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of microwave irradiation sessions required for treatment.
To perform MEA safely, Kanaoka et al4 presented guidelines for
2.45-GHz MEA procedures. Among the reported adverse events
caused by MEA, the most severe outcomes are uterine perforation
and heat damage to the extrauterine organs. To avoid the former
event, ongoing ultrasonographic monitoring and hysteroscopic ex-
amination during the procedure are recommended to allow obser-
vation of the ablated endometrial area. To avoid the latter event, it is
recommended that the myometrial layer of the area to be ablated
should have a depth of at least 10mm. This recommendation is based
on the results of the original study, which showed that a single ses-
sion of 2.45-GHz microwave irradiation with an output of 70 watts
for 50 seconds formed a lemon-shaped necrotic areawith awidth of
16 mm and a length of 20 mm around the tip of the applicator.4,5
Endometrial ablation, including MEA, has a higher latent risk in pa-
tientswho underwent a previous cesarean delivery.4,6 If the operator
grasps the thinness on the previous cesarean scar properly, he or she
can provideMEA and avoid irradiation sessions on the thin scar wall.
In the current study, six patients with a history of cesarean delivery
received MEA. They were safely treated with careful provision in
consideration of the thinness around the previous cesarean scar. All
of them obtained highly effective outcomes.
The short-term efﬁcacy rate of MEA for the treatment of
menorrhagia was estimated to be 94.7%. Moreover, a highly effec-
tive outcome was obtained in 84.2% of patients. Short-term efﬁcacy
of MEA reported in the recent literature is summarized in
Table 4.3,7e10 On the whole, the efﬁcacy rate for reducing the
menstrual bleeding volume is estimated to be ~90%, and the
postoperative amenorrhea rate is 20e40%. The effectiveness for
relieving concomitant menstrual pain is reportedly high as well. In
the current study, similar results were observed.
The optimal MEA outcomes were associated with a shorter
uterine corpus cavity. This result does not suggest that the factor
had a robust inﬂuence on the highly effective outcome because the
result was determined by univariate analysis. However, this prog-
nostic factor may help clinicians determine the likelihood that MEA
will produce positive outcomes in a particular patient.Womenwith
a uterine corpus cavity length of < 7 cm may obtain better out-
comes, whereas those with a longer uterine corpus cavity may be
more likely to require subsequent hormonal therapy or hysterec-
tomy postoperatively. A trend was observed that patients with
lower preoperative levels of menstrual pain and abnormal vaginal
bleeding may obtain better MEA outcomes, but this was not sig-
niﬁcant. Peeters et al6 similarly reported that short uterine depth
and no dysmenorrhea were prognostic factors for the success of
endometrial ablation to treat menorrhagia. This information may
help physicians plan individual therapeutic strategies in the man-
agement of menorrhagia.
A positive linear correlation was observed between the uterine
corpus cavity length and the number of microwave irradiationstrual Postoperative
amenorrhea rate
Amelioration of menstrual pain Subsequent
hysterectomy rate
41 4
41 72 7
32
31 81 2
34 VAS score of 4.2 improved to 1.3
53 VAS score of 7.5 improved to 0.5 9a
N. Matsumoto et al. / Gynecology and Minimally Invasive Therapy 4 (2015) 76e8080sessions required for treatment. As a rough estimate, a uterine
corpus cavity with a length of 5 cm generally required six micro-
wave irradiation sessions, one of 6 cm needed seven sessions, and
one of 7 cm required eight sessions. This guideline may assist MEA
operators in selecting the number of microwave irradiation ses-
sions, taking into account uterine size, uterine shape, organic
diagnosis, and previous history of cesarean delivery.
Since the introduction of MEA for the treatment of menorrhagia
in our hospital in 2012, the procedures have been shown to be both
effective and safe. In our experiences, the cases that do not have
very large cavities, protuberating submucosal myomas, and severe
endometriosis outside the uterus are considered to be positive in-
dications for MEA. Particularly for a case with large submucosal
myomas, Kanaoka et al11 developed and reported the system of
transcervical microwave myolysis. It seems to have potency;
however, it cannot be applied yet for approved treatment. We hope
to continue contributing to improvements in the provision and
research of this novel and useful therapy in Japan.
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